| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 03/06/2002 | CN1338937A Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| 03/06/2002 | CN1338456A Benzodiazapine compounds containing imidazole propanamido and its preparing process and application |
| 03/06/2002 | CN1338288A Medicine for taking care of eye health and its preparing process |
| 03/05/2002 | US6353032 Wetting agents for eyes and stimulants of ocular mucin production |
| 03/05/2002 | US6353022 Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
| 03/05/2002 | US6353012 15-Hydroxyeicosatetraenoic acid-related compounds and methods of use |
| 03/05/2002 | US6353010 Enzyme inhibitors tumor necrosis factor and phosphodiesterase for antiinflammatory agents |
| 03/05/2002 | US6352999 Drugs for nervous system disorders, parkinson's disease and antidepressants |
| 03/05/2002 | US6352990 CRF receptor antagonists and methods relating thereto |
| 03/05/2002 | US6352985 Benzimidazole compounds |
| 03/05/2002 | CA2266565C Azabicyclic rotomase inhibitors |
| 03/05/2002 | CA2207574C Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory products |
| 02/28/2002 | WO2002016434A1 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION |
| 02/28/2002 | WO2002016394A1 Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds |
| 02/28/2002 | WO2002016393A1 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016392A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016370A1 1h-imidazopyridine derivatives |
| 02/28/2002 | WO2002016352A1 Quinazoline derivatives |
| 02/28/2002 | WO2002016350A1 Amine derivatives |
| 02/28/2002 | WO2002016326A1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases |
| 02/28/2002 | WO2002016324A1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 02/28/2002 | WO2002016319A1 Novel thiourea compounds and the pharmaceutical compositions containing the same |
| 02/28/2002 | WO2002016318A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| 02/28/2002 | WO2002016311A1 Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient |
| 02/28/2002 | WO2002015942A1 Method for the identification of agents that inhibit or promote cataracts and uses thereof |
| 02/28/2002 | WO2002015941A1 A method for reducing stress-induced overproduction of neuropeptide y in an individual |
| 02/28/2002 | WO2002015933A2 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser |
| 02/28/2002 | WO2002015913A1 Treatment of trauma, and other indications |
| 02/28/2002 | WO2002015911A1 Lubricating agent and insertion aid solution for contact lens |
| 02/28/2002 | WO2002015907A1 Use of flupirtine to treat tinnitus |
| 02/28/2002 | WO2002015892A2 Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors |
| 02/28/2002 | WO2002015888A1 Drug-release controlling system |
| 02/28/2002 | WO2002015886A2 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015885A2 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015878A1 Aqueous suspension preparations |
| 02/28/2002 | WO2001079271A9 Albumin fusion proteins |
| 02/28/2002 | WO2001079258A9 Albumin fusion proteins |
| 02/28/2002 | WO2001076530A3 Il-8 receptor antagonists |
| 02/28/2002 | WO2001073029A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 02/28/2002 | WO2001072281A3 Microspheres for active embolization |
| 02/28/2002 | WO2001070255A3 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 02/28/2002 | WO2001068654A3 Tubulin binding ligands and corresponding prodrug constructs |
| 02/28/2002 | WO2001064639A3 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 02/28/2002 | WO2001060347A3 Method for treating ocular pain |
| 02/28/2002 | WO2001049309A3 Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue |
| 02/28/2002 | WO2001042216A3 Caspase inhibitors and uses thereof |
| 02/28/2002 | WO2001001970A3 New uses potassium channel openers, such as the treatment of epilepsy |
| 02/28/2002 | WO2000073307A8 Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors |
| 02/28/2002 | US20020026176 Devices for intraocular drug delivery |
| 02/28/2002 | US20020026051 Calcium channel antagonists with cardiovascular, antiasthmatic and antibronchoconstriction activity |
| 02/28/2002 | US20020025985 Apoptosis inhibitor |
| 02/28/2002 | US20020025966 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments |
| 02/28/2002 | US20020025934 Renin inhibitor |
| 02/28/2002 | US20020025558 Human MAD proteins and uses thereof |
| 02/28/2002 | CA2674888A1 Anti-ige vaccines |
| 02/28/2002 | CA2674838A1 Anti-ige vaccines |
| 02/28/2002 | CA2452346A1 Method for the identification of agents that inhibit or promote cataracts and uses thereof |
| 02/28/2002 | CA2425206A1 Treatment of trauma, and other indications |
| 02/28/2002 | CA2420283A1 T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection |
| 02/28/2002 | CA2420190A1 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2418730A1 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2417507A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| 02/28/2002 | CA2411924A1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting proteinkinases |
| 02/28/2002 | CA2356124A1 Anti-ige vaccines |
| 02/27/2002 | EP1181934A1 Inhibitors for optic hypofunction caused by optic nerve cell injury induced by factors other than optic circulatory disorder |
| 02/27/2002 | EP1181390A1 27 human secreted proteins |
| 02/27/2002 | EP1181385A2 Modulation of gene expression in gastrointestinal inflammation |
| 02/27/2002 | EP1181367A2 Polynucleotides and membrane-bound polypeptides encoded thereby |
| 02/27/2002 | EP1181316A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS |
| 02/27/2002 | EP1181305A1 Methods of modulating activity of prokaryotic ribosomes |
| 02/27/2002 | EP1181303A1 50 human secreted proteins |
| 02/27/2002 | EP1181288A1 Bicyclic oxazolidinones as antibacterial agent |
| 02/27/2002 | EP1181286A1 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides |
| 02/27/2002 | EP1181285A2 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 02/27/2002 | EP1181284A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use |
| 02/27/2002 | EP1181282A2 Benzothiazinone and benzoxazinone compounds |
| 02/27/2002 | EP1181054A1 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
| 02/27/2002 | EP1181051A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF IMMUNOLOGICALLY-MEDIATED DISEASES USING i MYCOBACTERIUM VACCAE /i |
| 02/27/2002 | EP1181039A2 Therapeutic uses of bpi protein products in humans with otitis media with effusion |
| 02/27/2002 | EP1181031A1 Novel antiangiogenic peptides |
| 02/27/2002 | EP1181017A1 Metalloprotease inhibitors |
| 02/27/2002 | EP0782447B1 Use of prostaglandins for the manufacture of a medicament for prevention and treatment of secondary cataract |
| 02/27/2002 | CN1337958A Compounds and methods for modulation of estroglen receptors |
| 02/27/2002 | CN1337953A New thryoid receptor ligands and process II |
| 02/27/2002 | CN1337952A 2,3,4,5-tetrahydro-1H-[1,4] benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors |
| 02/27/2002 | CN1337949A Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid as TACE inhibitor |
| 02/27/2002 | CN1337944A Acetylenic beta-sulfonamido and phosphinic acid amide hydroxamic acid as TACE inhibitors |
| 02/27/2002 | CN1337931A Retinoid antagonists and use thereof |
| 02/26/2002 | US6350857 Fifty-four homologue (ffh) from streptococcus pneumoniae |
| 02/26/2002 | US6350782 Use of basic amino acids derivatives for lowering ceramide levels |
| 02/26/2002 | US6350759 Dihydro- and tetrahydro-quinoline compounds |
| 02/26/2002 | US6350745 Thrombin inhibitors |
| 02/26/2002 | US6350598 MurD |
| 02/26/2002 | US6350457 Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae |
| 02/26/2002 | US6350442 Ocular treatment using cyclosporin-A derivatives |
| 02/26/2002 | CA2195094C Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases |
| 02/26/2002 | CA2025728C Antimicrobial compositions |
| 02/26/2002 | CA2024672C Indole, benzofuran,and benzothiophene containing lipoxygenase inhibiting compounds |
| 02/21/2002 | WO2002014369A2 Human kininogen d5 domain polypeptides and their use |
| 02/21/2002 | WO2002014349A2 Non-covalent inhibitors of urokinase and blood vessel formation |